Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.30
-0.8600-1.95%
Pre-market: 43.610.3100+0.72%04:16 EDT
Volume:3.35M
Turnover:145.42M
Market Cap:7.20B
PE:-12.44
High:44.19
Open:43.76
Low:42.79
Close:44.16
52wk High:86.74
52wk Low:42.63
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.36
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.36
PE(LYR):-18.18

Loading ...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment

Reuters
·
Aug 28

Ionis Pharmaceuticals, Inc. : Bmo Initiates Coverage with Market Perform Rating; Price Target $60

THOMSON REUTERS
·
Aug 19

BMO Capital starts Ionis at Market Perform pending better visibility

TIPRANKS
·
Aug 19

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Ionis Pharmaceuticals (IONS) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 14

Ionis Pharmaceuticals Earnings Call Highlights Pipeline And Growth

TIPRANKS
·
Aug 12

J.P. Morgan Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 10

Novartis Might Struggle to Clear Bar in Cholesterol Drug Trial

Dow Jones
·
Aug 10

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Aug 03

Ionis Director Michael R. Hayden Reports Acquisition of 20,000 Common Shares Worth $1,059,000

Reuters
·
Aug 01

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Benzinga Earnings
·
Jul 31

Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating

TIPRANKS
·
Jul 31

Ionis Pharmaceuticals is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

RBC Capital Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 30

Ionis Pharmaceuticals price target lowered to $115 from $125 at H.C. Wainwright

TIPRANKS
·
Jul 30

Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs

TIPRANKS
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30